The prognostic role of the preoperative absolute lymphocyte count and absolute monocyte count in patients with resected advanced melanoma

American Journal of Clinical Oncology: Cancer Clinical Trials

Volumn 38, Issue 3, 2015, Pages 252-258

  Rochet, Nicole M ^a   Kottschade, Lisa A ^a   Grotz, Travis E ^b   Porrata, Luis F ^b   Markovic, Svetomir N ^a,b  

^a MAYO CLINIC   (United States)

^b Department of Health Sciences Research   (United States)

Author keywords

absolute lymphocyte count; absolute monocyte count; advanced stage; malignant melanoma; survival

Indexed keywords

CANCER VACCINE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERFERON;

ADULT; ADVANCED CANCER; ARTICLE; BLOOD CELL COUNT; CANCER ADJUVANT THERAPY; CANCER GROWTH; CANCER PATIENT; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; FEMALE; HUMAN; HUMAN CELL; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MELANOMA; MONOCYTE COUNT; OVERALL SURVIVAL; PREOPERATIVE EVALUATION; RECURRENCE FREE SURVIVAL; RETROSPECTIVE STUDY; SYSTEMIC THERAPY; ADOLESCENT; AGED; BLOOD; DISEASE COURSE; DISEASE FREE SURVIVAL; LEUKOCYTE COUNT; LYMPHOCYTE; MIDDLE AGED; MONOCYTE; PATHOLOGY; PREOPERATIVE PERIOD; SURVIVAL RATE; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; LEUKOCYTE COUNT; LYMPHOCYTE COUNT; LYMPHOCYTES; MALE; MELANOMA; MIDDLE AGED; MONOCYTES; NEOPLASM STAGING; PREOPERATIVE PERIOD; RETROSPECTIVE STUDIES; SURVIVAL RATE; YOUNG ADULT;

EID: 84930764131     PISSN: 02773732     EISSN: 1537453X     Source Type: Journal    
DOI: 10.1097/COC.0b013e31829b5605     Document Type: Article

References (36)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin. 2013;63:11-30.
2. Balch CM, Gershenwald JE, Soong SJ, et al. Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol. 2009; 27:6199-6206.
3. + T cells. World J Surg. 1995;19:352-358.
4. Taylor RC, Patel A, Panageas KS, et al. Tumor-infiltrating lymphocytes predict sentinel lymph node positivity in patients with cutaneous melanoma. J Clin Oncol. 2007;25:869-875.
5. Clemente CG, Mihm MC Jr, Bufalino R, et al. Prognostic value of tumor infiltrating lymphocytes in the vertical growth phase of primary cutaneous melanoma. Cancer. 1996;77:1303-1310.
6. Hakansson A, Gustafsson B, Krysander L, et al. Tumour-infiltrating lymphocytes in metastatic malignant melanoma and response to interferon alpha treatment. Br J Cancer. 1996;74:670-676.
7. Mansfield AS, Holtan SG, Grotz TE, et al. Regional immunity in melanoma: immunosuppressive changes precede nodal metastasis. Mod Pathol. 2011;24:487-494.
8. Gogas H, Ioannovich J, Dafni U, et al. Prognostic significance of autoimmunity during treatment of melanoma with interferon. N Engl J Med. 2006;354:709-718.
9. Ege H, Gertz MA, Markovic SN, et al. Prediction of survival using absolute lymphocyte count for newly diagnosed patients with multiple myeloma: a retrospective study. Br J Haematol. 2008; 141:792-798.
10. Siddiqui M, Ristow K, Markovic SN, et al. Absolute lymphocyte count predicts overall survival in follicular lymphomas. Br J Haematol. 2006;134:596-601.
11. Wilcox RA, Ristow K, Habermann TM, et al. The absolute monocyte and lymphocyte prognostic score predicts survival and identifies high-risk patients in diffuse large-B-cell lymphoma. Leukemia. 2011;25:1502-1509.
12. Porrata LF, Ristow K, Colgan J, et al. Peripheral blood lymphocyte/monocyte ratio at diagnosis and survival in classical Hodgkin lymphoma. Haematologica. 2012;97:262-269.
13. Choi CH, Kang H, Kim WY, et al. Prognostic value of baseline lymphocyte count in cervical carcinoma treated with concurrent chemoradiation. Int J Radiat Oncol Biol Phys. 2008;71:199-204.
14. Schmidt H, Bastholt L, Geertsen P, et al. Elevated neutrophil and monocyte counts in peripheral blood are associated with poor survival in patients with metastatic melanoma: a prognostic model. Br J Cancer. 2005;93:273-278.
15. Thoma MD, Huneke TJ, Decook LJ, et al. Peripheral blood lymphocyte and monocyte recovery and survival in acute leukemia postmyeloablative allogeneic hematopoietic stem cell transplant. Biol Blood Marrow Transplant. 2012;18:600-607.
16. Ku GY, Yuan J, Page DB, et al. Single-institution experience with ipilimumab in advanced melanoma patients in the compassionate use setting: lymphocyte count after 2 doses correlates with survival. Cancer. 2010;116:1767-1775.
17. Harris PA, Taylor R, Thielke R, et al. Research electronic data capture (REDCap)-A metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inform. 2009;42:377-381.
18. Hodi FS, O'Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010;363:711-723.
19. Boasberg PD, Hoon DS, Piro LD, et al. Enhanced survival associated with vitiligo expression during maintenance biotherapy for metastatic melanoma. J Invest Dermatol. 2006;126:2658-2663.
20. Joao C, Porrata LF, Inwards DJ, et al. Early lymphocyte recovery after autologous stem cell transplantation predicts superior survival in mantle-cell lymphoma. Bone Marrow Transplant. 2006;37:865-871.
21. Porrata LF, Gertz MA, Inwards DJ, et al. Early lymphocyte recovery predicts superior survival after autologous hematopoietic stem cell transplantation in multiple myeloma or non-Hodgkin lymphoma. Blood. 2001;98:579-585.
22. Porrata LF, Inwards DJ, Ansell SM, et al. Early lymphocyte recovery predicts superior survival after autologous stem cell transplantation in non-Hodgkin lymphoma: a prospective study. Biol Blood Marrow Transplant. 2008;14:807-816.
23. Porrata LF, Inwards DJ, Ansell SM, et al. New-onset lymphopenia assessed during routine follow-up is a risk factor for relapse postautologous peripheral blood hematopoietic stem cell transplantation in patients with diffuse large B-cell lymphoma. Biol Blood Marrow Transplant. 2010;16:376-383.
24. Porrata LF, Inwards DJ, Micallef IN, et al. Early lymphocyte recovery post-autologous haematopoietic stem cell transplantation is associated with better survival in Hodgkin's disease. Br J Haematol. 2002;117:629-633.
25. Porrata LF, Litzow MR, Tefferi A, et al. Early lymphocyte recovery is a predictive factor for prolonged survival after autologous hematopoietic stem cell transplantation for acute myelogenous leukemia. Leukemia. 2002;16:1311-1318.
26. Porrata LF, Ingle JN, Litzow MR, et al. Prolonged survival associated with early lymphocyte recovery after autologous hematopoietic stem cell transplantation for patients with metastatic breast cancer. Bone Marrow Transplant. 2001;28:865-871.
27. Sosman JA, Moon J, Tuthill RJ, et al. A phase 2 trial of complete resection for stage IV melanoma: results of Southwest Oncology Group Clinical Trial S9430. Cancer. 2011;117:4740-4746.
28. Korn EL, Liu PY, Lee SJ, et al. Meta-analysis of phase II cooperative group trials in metastatic stage IV melanoma to determine progression-free and overall survival benchmarks for future phase II trials. J Clin Oncol. 2008;26:527-534.
29. + lymphocytes during chemo-immunotherapy in metastatic melanoma. Melanoma Res. 2004;14: 493-500.
30. + ratio as a prognostic factor in patients with metastatic melanoma receiving chemoimmunotherapy. J Clin Oncol. 1996;14: 1690-1696.
31. Bogunovic D, O'Neill DW, Belitskaya-Levy I, et al. Immune profile and mitotic index of metastatic melanoma lesions enhance clinical staging in predicting patient survival. Proc Natl Acad Sci USA. 2009;106:20429-20434.
32. Mihm MC Jr, Clemente CG, Cascinelli N. Tumor infiltrating lymphocytes in lymph node melanoma metastases: a histopatho-logic prognostic indicator and an expression of local immune response. Lab Invest. 1996;74:43-47.
33. Torisu-Itakura H, Lee JH, Huynh Y, et al. Monocyte-derived IL-10 expression predicts prognosis of stage IV melanoma patients. J Immunother. 2007;30:831-838.
34. Jensen TO, Schmidt H, Moller HJ, et al. Macrophage markers in serum and tumor have prognostic impact in American Joint Committee on Cancer stage I/II melanoma. J Clin Oncol. 2009;27:3330-3337.
35. Moestrup SK, HJ M. CD163: a regulated hemoglobin scavenger receptor with a role in the antiinflammatory response. Ann Med. 2004;36:347-354.
36. Nguyen TT, Schwartz EJ, West RB, et al. Expression of CD163 (hemoglobin scavenger receptor) in normal tissues, lymphomas, carcinomas, and sarcomas is largely restricted to the monocyte/macrophage lineage. Am J Surg Pathol. 2005;29:617-624.